Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Arboviral Encephalitis

Arboviral Encephalitis

Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...

Enzyme-Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sub-neutralizing concentrations of Zika virus IgM monoclonal antibodies reduce IgG-mediated antibody-dependent enhancement of infectivity.

bioRxiv : the preprint server for biology·2026

Same author

A systems immunology approach reveals divergent immune profiles of RSV and SARS-CoV-2 infections in infants.

Science translational medicine·2026

Same author

Integrated longitudinal transcriptomic and proteomic analysis of the murine lung response to influenza a virus.

American journal of respiratory cell and molecular biology·2025

Same author

Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.

The Journal of experimental medicine·2025

Same author

Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques.

Communications medicine·2025

Same author

Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1.

Vaccines·2025

Search research articles

Related Experiment Video

Updated: May 17, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Julia L Hurwitz¹, Xiaoyan Zhan, Scott A Brown

¹Departments of Immunology ; Infectious Diseases, St. Jude Children's Research Hospital ; Departments of Pathology.

The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG

|October 12, 2012

Summary

Researchers are developing an HIV-1 vaccine using a cocktail of diverse envelope proteins to prevent infection. This strategy aims to elicit broad immune responses, similar to successful vaccines for other diseases.

Keywords:

HIV-1 vaccine Immunology clinical trial envelope multi-vector

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8⁺ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Related Experiment Videos

Last Updated: May 17, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8⁺ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Area of Science:

Immunology
Vaccinology
Virology

Background:

Human Immunodeficiency Virus type 1 (HIV-1) infection is mediated by diverse envelope protein structures.
A single vaccine may not be sufficient to elicit protective immunity against all HIV-1 variants.

Purpose of the Study:

To develop a novel HIV-1 vaccine strategy using a cocktail of immunodominant envelope proteins.
To elicit broad lymphocyte populations capable of preventing HIV-1 infection.

Main Methods:

Utilizing three recombinant vector systems for envelope cocktail delivery: DNA, vaccinia virus, and purified protein.
Conducting Phase I safety trials for individual vector systems.
Initiating a new FDA-approved clinical trial combining diverse envelopes and vectors in a prime-boost regimen.

Main Results:

Individual vector systems have undergone Phase I safety trials.
A prime-boost vaccination regimen combining multiple vectors and envelopes is under investigation.
The study aims to test the efficacy of a multi-vector, multi-envelope vaccine.

Conclusions:

A cocktail vaccine approach is necessary to address the diversity of HIV-1 envelope proteins.
The multi-vector, multi-envelope prime-boost strategy is being evaluated for its ability to induce protective immunity.
This research seeks to elicit diverse B- and T-cell responses for HIV-1 prevention.